Hyperinflammation in Patients with Chronic Granulomatous Disease Leads to Impairment of Hematopoietic Stem Cell Functions
Overview
Authors
Affiliations
Background: Defects in phagocytic nicotinamide adenine dinucleotide phosphate oxidase 2 (NOX2) function cause chronic granulomatous disease (CGD), a primary immunodeficiency characterized by dysfunctional microbicidal activity and chronic inflammation.
Objective: We sought to study the effect of chronic inflammation on the hematopoietic compartment in patients and mice with X-linked chronic granulomatous disease (X-CGD).
Methods: We used immunostaining and functional analyses to study the hematopoietic compartment in patients with CGD.
Results: An analysis of bone marrow cells from patients and mice with X-CGD revealed a dysregulated hematopoiesis characterized by increased numbers of hematopoietic progenitor cells (HPCs) at the expense of repopulating hematopoietic stem cells (HSCs). In patients with X-CGD, there was a clear reduction in the proportion of HSCs in bone marrow and peripheral blood, and they were also more rapidly exhausted after in vitro culture. In mice with X-CGD, increased cycling of HSCs, expansion of HPCs, and impaired long-term engraftment capacity were found to be associated with high concentrations of proinflammatory cytokines, including IL-1β. Treatment of wild-type mice with IL-1β induced enhanced cell-cycle entry of HSCs, expansion of HPCs, and defects in long-term engraftment, mimicking the effects observed in mice with X-CGD. Inhibition of cytokine signaling in mice with X-CGD reduced HPC numbers but had only minor effects on the repopulating ability of HSCs.
Conclusions: Persistent chronic inflammation in patients with CGD is associated with hematopoietic proliferative stress, leading to a decrease in the functional activity of HSCs. Our observations have clinical implications for the development of successful autologous cell therapy approaches.
Hematopoietic stem cell metabolism within the bone marrow niche - insights and opportunities.
Kemna K, van der Burg M, Lankester A, Giera M Bioessays. 2024; 47(2):e2400154.
PMID: 39506498 PMC: 11755706. DOI: 10.1002/bies.202400154.
Raimondi F, Siow K, Wrona D, Fuster-Garcia C, Pastukhov O, Schmitz M Commun Biol. 2024; 7(1):1291.
PMID: 39384978 PMC: 11464842. DOI: 10.1038/s42003-024-06959-z.
Khorashad J, Rizzo S, Tonks A Cancer Drug Resist. 2024; 7:5.
PMID: 38434766 PMC: 10905166. DOI: 10.20517/cdr.2023.125.
Valeri E, Unali G, Piras F, Abou-Alezz M, Pais G, Benedicenti F Mol Ther. 2023; 32(1):124-139.
PMID: 37990494 PMC: 10787167. DOI: 10.1016/j.ymthe.2023.11.020.
Whittaker T, Santilli G Mol Ther. 2023; 31(12):3367-3368.
PMID: 37980903 PMC: 10727967. DOI: 10.1016/j.ymthe.2023.11.007.